Timothy A. Masterson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Timothy A. Masterson has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Clint Cary
Indiana Univ, Dept Urol, Indianapolis, IN 46202 USA
7 shared publications- Clint Cary
Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana
4 shared publications Liang Cheng
4 shared publications- Richard S. Foster
Indiana University School of Medicine, Indiana Cancer Pavilion
4 shared publications - Liang Cheng
Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, and Brown University Health, Providence, RI
3 shared publications Michael O. Koch
3 shared publications
Latest Publications
- 19 May 2026
- Published by Springer Nature
- p. 369-420
Oncologic Emergencies
- 18 May 2024
- Published by Elsevier in Urologic Clinics of North America
- Vol. 51 (3) , 407-419
Retroperitoneal Lymph Node Dissection
- 18 May 2024
- Published by Elsevier in Urologic Clinics of North America
- Vol. 51 (3) , 407-419
Retroperitoneal Lymph Node Dissection
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (3) , 641-649
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor
Purpose: The optimal management of patients with metastatic germ cell tumors who achieve a complete response (CR) after first-line chemotherapy remains unsettled. This study reports long-term outcomes of patients with metastatic germ cell tumor managed with surveillance after achieving a CR to first-line chemotherapy. Materials and Methods: Patients with metastatic nonseminomatous germ cell tumor treated at Indiana University between 1990 and 2017 who achieved a CR after first-line chemotherapy and were monitored with surveillance were retrospectively analyzed. CR was defined as normalization of tumor markers AFP and hCG, and no residual mass >1 cm in long axis. Kaplan-Meier methods were used to analyze progression-free survival (PFS) and overall survival (OS). Results: Three hundred sixty-seven patients achieved a CR and were managed with surveillance. After a median followup of 4.97 years, 34 patients had disease progression. At most recent followup, 346 (94%) patients were alive with no evidence of disease, 10 patients (2.7%) died of their disease, 5 (1.4%) died of other causes and 6 (1.6%) were lost to followup. The estimated 2-year PFS was 91% (95% CI: 87%–94%) and 2-year OS was 98% (95% CI: 96%–99%). The estimated 2-year PFS by International Germ Cell Cancer Collaborative Group risk category was 92% for good vs 90% for intermediate vs 87% for poor risk (p=0.15), and the estimated 2-year OS was 99% for good vs 96% for intermediate vs 93% for poor risk disease (p=0.001). Conclusions: Patients with metastatic nonseminomatous germ cell tumor who achieve a CR after first-line chemotherapy can be observed. Most patients who relapse can be salvaged with surgery and/or chemotherapy.
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (3) , 641-649
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor
Purpose: The optimal management of patients with metastatic germ cell tumors who achieve a complete response (CR) after first-line chemotherapy remains unsettled. This study reports long-term outcomes of patients with metastatic germ cell tumor managed with surveillance after achieving a CR to first-line chemotherapy. Materials and Methods: Patients with metastatic nonseminomatous germ cell tumor treated at Indiana University between 1990 and 2017 who achieved a CR after first-line chemotherapy and were monitored with surveillance were retrospectively analyzed. CR was defined as normalization of tumor markers AFP and hCG, and no residual mass >1 cm in long axis. Kaplan-Meier methods were used to analyze progression-free survival (PFS) and overall survival (OS). Results: Three hundred sixty-seven patients achieved a CR and were managed with surveillance. After a median followup of 4.97 years, 34 patients had disease progression. At most recent followup, 346 (94%) patients were alive with no evidence of disease, 10 patients (2.7%) died of their disease, 5 (1.4%) died of other causes and 6 (1.6%) were lost to followup. The estimated 2-year PFS was 91% (95% CI: 87%–94%) and 2-year OS was 98% (95% CI: 96%–99%). The estimated 2-year PFS by International Germ Cell Cancer Collaborative Group risk category was 92% for good vs 90% for intermediate vs 87% for poor risk (p=0.15), and the estimated 2-year OS was 99% for good vs 96% for intermediate vs 93% for poor risk disease (p=0.001). Conclusions: Patients with metastatic nonseminomatous germ cell tumor who achieve a CR after first-line chemotherapy can be observed. Most patients who relapse can be salvaged with surgery and/or chemotherapy.
- 1 April 2022
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (Supplement) , S90-S91
179 Safety and Feasibility of Platelet-Rich Plasma Injections for Peyronie's Disease: Update From a Single-center Double-blind Placebo-controlled Randomized Trial
Introduction Peyronie's Disease (PD) is prevalent in approximately 7.1% of the general population. Current treatment approaches include medical therapy and surgical intervention, and intervention only occurs once the disease process has entered the chronic, stable phase. The only FDA-approved medical therapy involves use of intralesional collagenase clostridium histolyticum injection and surgical interventions include tunica albuginea plication, plaque excision without grafting, or placement of penile prothesis. Additional PD therapies are needed as current treatment modalities have limited efficacy and considerable side effects. Platelet-derived therapies have seen increased use across various specialties in medicine, especially in orthopedics, due to their potential ability in wound healing and tissue regeneration. As calcified scar plaques are frequently identified in PD patients, autologous platelet rich plasma (PRP) may prove to be a viable treatment for this patient population. Objective We reviewed an initial series of patients receiving PRP vs placebo for PD to assess safety and feasibility among men recruited in a double-blind placebo controlled single-center clinical trial. Methods We reviewed data for men recruited into the clinical trial treated with PRP vs placebo at our center from April 2021 to July 2021. Patients were observed immediately post-injection and at follow-up for complications and tolerability. Where applicable, International Index of Erectile Function (IIEF-5) scores were reviewed before and after injections for PD. Results We report data from the men who have completed 2 completed injections (PRP or placebo). No post-procedural minor adverse events were seen in any of the men. None of them reported adverse effects such as penile bruising, swelling, edema, allergy, penile fracture, or mild pain at injection site. No patients experienced complications at follow-up. No worsening curvature was observed in men completing pre/post evaluations. Conclusions PRP appears to be a safe and feasible treatment modality in patients with PD from our limited data accumulated thus far in our ongoing randomized placebo-controlled trial with PRP for PD. Our study is the first study in the USA accruing men with PRP for PD and believe that safety and efficacy data accumulated from our study will be important for patient counseling. Disclosure No
- 1 April 2022
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 19 (Supplement) , S90-S91
179 Safety and Feasibility of Platelet-Rich Plasma Injections for Peyronie's Disease: Update From a Single-center Double-blind Placebo-controlled Randomized Trial
Introduction Peyronie's Disease (PD) is prevalent in approximately 7.1% of the general population. Current treatment approaches include medical therapy and surgical intervention, and intervention only occurs once the disease process has entered the chronic, stable phase. The only FDA-approved medical therapy involves use of intralesional collagenase clostridium histolyticum injection and surgical interventions include tunica albuginea plication, plaque excision without grafting, or placement of penile prothesis. Additional PD therapies are needed as current treatment modalities have limited efficacy and considerable side effects. Platelet-derived therapies have seen increased use across various specialties in medicine, especially in orthopedics, due to their potential ability in wound healing and tissue regeneration. As calcified scar plaques are frequently identified in PD patients, autologous platelet rich plasma (PRP) may prove to be a viable treatment for this patient population. Objective We reviewed an initial series of patients receiving PRP vs placebo for PD to assess safety and feasibility among men recruited in a double-blind placebo controlled single-center clinical trial. Methods We reviewed data for men recruited into the clinical trial treated with PRP vs placebo at our center from April 2021 to July 2021. Patients were observed immediately post-injection and at follow-up for complications and tolerability. Where applicable, International Index of Erectile Function (IIEF-5) scores were reviewed before and after injections for PD. Results We report data from the men who have completed 2 completed injections (PRP or placebo). No post-procedural minor adverse events were seen in any of the men. None of them reported adverse effects such as penile bruising, swelling, edema, allergy, penile fracture, or mild pain at injection site. No patients experienced complications at follow-up. No worsening curvature was observed in men completing pre/post evaluations. Conclusions PRP appears to be a safe and feasible treatment modality in patients with PD from our limited data accumulated thus far in our ongoing randomized placebo-controlled trial with PRP for PD. Our study is the first study in the USA accruing men with PRP for PD and believe that safety and efficacy data accumulated from our study will be important for patient counseling. Disclosure No
- 1 November 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (11) , 789.e1-789.e7
Definitive surgical therapy for refractory radiation cystitis: Evaluating effectiveness, tolerability, and extent of surgical approach
- 1 November 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (11) , 789.e1-789.e7
Definitive surgical therapy for refractory radiation cystitis: Evaluating effectiveness, tolerability, and extent of surgical approach
- 1 October 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (10) , 698-703
Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers
- 1 October 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (10) , 698-703
Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers
- 1 September 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (9) , 561-568
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges
- 1 September 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (9) , 561-568
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges
- Open Access
- 1 January 2020
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 9 (S1) , S83-S90
Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes
The purpose of this review is to present a comprehensive and updated review of the literature and summary of the indications, risks and outcomes related to salvage, desperation and late relapse surgery for advanced testicular cancer. After completing a thorough review of the current literature, this review has attempted to provide an overview of the indications for salvage, desperation and late relapse retroperitoneal lymph node dissection (RPLND) followed by a summary of the histopathologic and clinical outcomes regarding each. Recent literature, combined with a significant contribution from historical studies suggest that while testicular cancer is a relatively uncommon malignancy overall, it represents the most common solid organ malignancy for young men. Although a significant number of men are cured with a combination of first-line treatments, the remaining men are a diverse and often challenging cohort who require the benefit of expertise to improve their outcomes. The role of surgical strategies in the salvage, desperation and late relapse settings is unquestionable, although the most important question remains who will benefit. This often requires a multi-disciplinary approach at centers specializing in this disease process in order to recognize who should get surgery, what surgery to do and how to minimize the potential morbidity associated with the operation.
- 1 January 2020
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 9 (S1) , S83-S90
Open AccessSurgical salvage in patients with advanced testicular cancer: indications, risks and outcomes
The purpose of this review is to present a comprehensive and updated review of the literature and summary of the indications, risks and outcomes related to salvage, desperation and late relapse surgery for advanced testicular cancer. After completing a thorough review of the current literature, this review has attempted to provide an overview of the indications for salvage, desperation and late relapse retroperitoneal lymph node dissection (RPLND) followed by a summary of the histopathologic and clinical outcomes regarding each. Recent literature, combined with a significant contribution from historical studies suggest that while testicular cancer is a relatively uncommon malignancy overall, it represents the most common solid organ malignancy for young men. Although a significant number of men are cured with a combination of first-line treatments, the remaining men are a diverse and often challenging cohort who require the benefit of expertise to improve their outcomes. The role of surgical strategies in the salvage, desperation and late relapse settings is unquestionable, although the most important question remains who will benefit. This often requires a multi-disciplinary approach at centers specializing in this disease process in order to recognize who should get surgery, what surgery to do and how to minimize the potential morbidity associated with the operation.
- Open Access
- 22 February 2019
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 10 (3) , 1405-1419
Cylindrical illumination with angular coupling for whole-prostate photoacoustic tomography
Current diagnosis of prostate cancer relies on histological analysis of tissue samples acquired by biopsy, which could benefit from real-time identification of suspicious lesions. Photoacoustic tomography has the potential to provide real-time targets for prostate biopsy guidance with chemical selectivity, but light delivered from the rectal cavity has been unable to penetrate to the anterior prostate. To overcome this barrier, a urethral device with cylindrical illumination is developed for whole-prostate imaging, and its performance as a function of angular light coupling is evaluated with a prostate-mimicking phantom.
- 22 February 2019
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 10 (3) , 1405-1419
Open AccessCylindrical illumination with angular coupling for whole-prostate photoacoustic tomography
Current diagnosis of prostate cancer relies on histological analysis of tissue samples acquired by biopsy, which could benefit from real-time identification of suspicious lesions. Photoacoustic tomography has the potential to provide real-time targets for prostate biopsy guidance with chemical selectivity, but light delivered from the rectal cavity has been unable to penetrate to the anterior prostate. To overcome this barrier, a urethral device with cylindrical illumination is developed for whole-prostate imaging, and its performance as a function of angular light coupling is evaluated with a prostate-mimicking phantom.